We Need Your Help! PDF Print E-mail
Tuesday, 09 March 2010 20:51
Today, the Scleroderma Care Foundation embarks upon a mission of vital importance, and we are counting on your help.

One of our dearest Scleroderma patients and friend, Agnes Basil-James, is on the verge of Renal or kidney failure and we are seeking out a qualified kidney donor. Currently, her kidneys are operating at around 2% efficiency and she undergoes dialysis treatment several times per week. Agnes is also the longest known survivor of Scleroderma in Trinidad & Tobago, having been diagnosed with the disease in 1986, some 24 years ago.

As many are aware, Systemic Scleroderma can cause musculoskeletal, pulmonary, gastrointestinal, renal, and other complications. Renal involvement in Scleroderma is typically considered a poor prognostic factor and frequent cause of death. Approximately 5-10% of all Scleroderma patients develop renal crisis at some point in the course of their disease, and is most common in diffuse coetaneous Scleroderma, often associated with antibodies against RNA polymerase (in 59% of cases). Many proceed to dialysis, although this can be stopped within three years in about a third of all cases.

Our programme, for as long as it takes, would seek to find an applicable donor for Agnes. From today, we would be featuring several articles on our site, on the nature and function of the kidneys, and associated renal involvement in Scleroderma. We also seek to provide some assistive and invaluable information on how you can become an organ donor yourself, along with tips for taking much better care of your very own kidneys.

It is our very sincere hope that someone out there, with blood group O, reading this, would be willing to come forward and assist Agnes. We would also like to encourage everyone reading this to please share with family, friends, co-workers, and associates, as our request for assistance may just reach the right person.

Agnes has been so kind as to share with us all, her story, which you can read here. For more information, please do feel free to contact us via email here, or phone at 756-3930 or 685-3213. Also, join us on Facebook or Twitter, where we would post updates as we progress.

Thank you.

Adelwyn Holder
President, Scleroderma Care Foundation
 
More articles :

» ArGentis Seeks More Funding After Obtaining Patent for ARG201 Therapy

ArGentis Pharmaceuticals LLC has received a patent for its scleroderma therapy while finalizing plans for a Phase IIb trial for the treatment known as ARG201.The patent comes nearly two years after it was developed by University of Tennessee Health...

» Calcinosis

Background:The Foundation has recently received some feedback from some members of the public asking for more information regarding the condition known as Calcinosis. As part of our efforts we sought to provide a brief, yet informative insight into...

» Do You Need To Alter Your Diet?

According to Chrissy Carroll, a registered dietitian and certified personal trainer with the , Scleroderma can present differently in each affected person, and diet recommendations are typically targeted toward specific symptoms. She indicated that...

» Egr-1: A Target for Scleroderma Therapy

Two separate research groups funded by the (NIAMS) have discovered that the molecule EGR-1 (early growth response 1), which regulates gene expression, plays a central role in the development of fibrosis, a condition in which organ-supporting tissue...

» What are the Early Symptoms of Scleroderma?

Scleroderma is a term used to describe a group of rare, chronic diseases characterized by unusual tightening and hardening of the connective tissues and skin. There are two major types of : localized, which only affects the skin; and systemic, which...

» Modulation of Fibrosis in Systemic Sclerosis by Nitric Oxide and Antioxidants

Systemic sclerosis is a multisystem, connective tissue disease of unknown aetiology characterized by vascular dysfunction, autoimmunity, and enhanced fibroblast activity resulting in fibrosis of the skin, heart, and lungs, and ultimately internal...